Document Detail

Glutamate inhibition in MS: the neuroprotective properties of riluzole.
MedLine Citation:
PMID:  15949499     Owner:  NLM     Status:  MEDLINE    
In addition to demyelination and damage to oligodendrocytes, axonal injury and neuronal cell death are dominating histopathological characteristics of multiple sclerosis (MS). Still little is known about the cause of the damage. Extracellular accumulation of glutamate contributes to excitotoxic injury of neurons and glial cells, suggesting that the maintenance of subtoxic extracellular glutamate levels may be crucial. Riluzole is a neuroprotective agent that inhibits the release of glutamate from nerve terminals and modulates glutamate, i.e., kainate and NMDA receptors. It inhibits excitotoxic injury in several experimental models of neurodegenerative disease. We performed a small run-in versus treatment MR-monitored pilot study in 16 primary progressive MS patients. The results suggest that riluzole reduces the rate of cervical cord atrophy and the development of T1 hypointense lesions on magnetic resonance imaging in primary progressive MS. The rate of brain atrophy was only slightly decreased. The results indicate an effect on mechanisms involving lesion evolution and axonal loss, but no clear effect on new lesion formation. However, the data suffer from several limitations and must be confirmed in future trials.
Joep Killestein; Nynke F Kalkers; Chris H Polman
Related Documents :
11486649 - Sequential mr studies of a patient with white matter disease presenting psychotic sympt...
18208869 - Large-scale, multicentre, quantitative mri study of brain and cord damage in primary pr...
3614649 - Evidence for central nervous system demyelination in chronic inflammatory demyelinating...
6538339 - Computed tomographic brain scan of thrombotic thrombocytopenic purpura.
4026629 - Magnetic resonance imaging and other techniques in the diagnosis of multiple sclerosis.
11433209 - Mr proton spectroscopy in patients with cns involvement in bourneville's disease.
8129659 - The role of fat-suppression technique and gadopentetate dimeglumine in magnetic resonan...
24931739 - The utility of dual bioelectrical impedance analysis in detecting intra-abdominal fat a...
7860409 - The use of digitally reconstructed radiographs for three-dimensional treatment planning...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article     Date:  2005-04-20
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  233     ISSN:  0022-510X     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-13     Completed Date:  2005-08-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  113-5     Citation Subset:  IM    
Department of Neurology, VU Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Follow-Up Studies
Glutamic Acid / metabolism*
Magnetic Resonance Imaging / methods
Middle Aged
Multiple Sclerosis / drug therapy*,  metabolism,  pathology
Neuroprotective Agents / therapeutic use*
Riluzole / therapeutic use*
Spinal Cord / pathology
Reg. No./Substance:
0/Neuroprotective Agents; 1744-22-5/Riluzole; 56-86-0/Glutamic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanisms of CNS remyelination--the key to therapeutic advances.
Next Document:  Transplanted human bone marrow cells generate new brain cells.